Scalper1 News
Valeant Pharmaceuticals International (VRX) early Thursday reported an in-line Q2 and lowered its guidance, though its sales guidance for the next two years was above consensus. Valeant was down more than 8% in midday trading in the stock market today, near 115 and within pennies of a nearly eight-month low. Valeant’s cash earnings rose 43% over the year-earlier quarter to $1.91 a share, beating analysts’ estimates by a penny. Sales climbed 86% to Scalper1 News
Scalper1 News